Clinical Effectiveness Group

Updates & News menu

Updates & News


Suspected COVID-19 in Primary Care: How GP Records Contribute to Understanding Differences in Prevalence by Ethnicity.

Suspected COVID-19 in primary care: how GP records contribute to understanding differences in prevalence by ethnicity. [PDF 731KB]

Also see our Twitter for more news & updates

Our working arrangements during the COVID-19 pandemic

In light of Covid-19 the CEG team will be working from home from Thursday 19th March.  We are reviewing options to reduce face to face contacts and travel. 

Tele-support We will support practices via e-mail and could also offer Zoom or Skype. 

Direct log-in to practices  We will ask practices to provide us with a login where needed so we can review and address any problems.  Practices will still need to approve this individually and monitor as they would any other external contractor.

We endeavour to maintain normal levels of service during this time and will continue to deliver our contracted dashboards which will be hosted in CEG website.  We will be updating templates/protocols/documents as required and will be maintaining our suite of searches.


East London Community Renal Clinic featured in NHS Long Term Plan launched on 7th January 2019

The latest NHS Long Term Plan was launched on 7 January.  It is an ambitious vision to improve NHS care with an increased focus on prevention and digital solutions.

The innovative east London Community Renal Clinic, developed jointly by CCGs, the Clinical Effectiveness Group and Barts Renal department is featured as a case study in the opening chapter:  A new service model for the 21st century”.




GPs at the DeepEnd 

The Deep End Project started in Glasgow with Prof Graham Watt who got the 100 most deprived GP practices in Scotland to regular meetings to address the particular needs of their disadvantaged patients.

GPs at the Deep End have been highly successful in advocating for their patients and campaigning for services and resources to meet the increased needs of practice populations in areas of deprivation.

The Deep End model has since spread throughout the world with practices in areas of concentrated disadvantage grouping together to share ideas, get involved in education and training for the specific challenges of deprivation and expand the field of research of primary care's role in addressing the causes and consequences of health inequalities. There are now DeepEnd projects in Dublin, Manchester, Humberside, Sheffield and elsewhere


A recent conference held in Glasgow in 2019 was inspirational for those that attended – you can view the presentations on YouTube and also download the presenters slides from this weblink.

The presentation by Austin O’ Carroll was particularly memorable and highly recommended!

Download Presenter slides here

Watch Presentation on YouTube here


There is also a book edited by Prof Watt including contributions by a number of the speakers – again highly recommended reading.



Newham, Tower Hamlets, City and Hackney Prescribing Improvement (31/8/2018)

CEG and prescribing advisors in Newham, City and Hackney and Tower Hamlets CCGs have promoted medicines optimisation and safety for a number of different medicines since 2015. In the year 2017-18 there was improvement in some measures but no change in others.

IMPROVEMENT  % change and latest 2018 (%)

Use of high intensity statins (atrovastatin 40mg or 80mg) in people with CHD, stroke/TIA, PAD, T2 diabetes.

This averages 41% across all 3 CCGs and increased by 2.3% 2017-18.

2018 TH +2% (46.4%)   C&H +4% (46.7%)      NH +1% (33.0%)

Reduced ICS in mild/moderate COPD

This average 38% across all 3 CCGs and reduced by 3.7% with marked differences between CCGs: 

2018 TH -7% (32.0%)    C&H -3% (35.0%)       NH -1% (47.1%)


8% of people with CVD* still prescribed NSAIDs      *(IHD,stroke/TIA, PAD,HF,CKD)

11% of people with Asthma prescribed salbutamol >12 and ICS<6 inhalers

– possibly reduced by 2% in C&H.

6% TH, 9% C&H and NH:  %  Long acting analogue Insulin in people with T2 diabetes

Return to top